Addition of liraglutide vs addition of a single dose of insulin aspart to insulin degludec plus metformin in patients with type 2 diabetes

被引：0
|
作者：
Mathieu, C. [1 ]
Rodbard, H. W. [2 ]
Cariou, B. [3 ]
Handelsman, Y.
Philis-Tsimikas, A. [4 ]
Francisco, A. Ocampo [5 ]
Rana, A. [5 ]
Zinman, B. [6 ]
机构：
[1] UZ Leuven, Louvain, Belgium
[2] Endocrine & Metab Consultants, Rockville, MD USA
[3] Nantes Univ Hosp, Nantes, France
[4] Scripps Whittier Diabet Inst, La Jolla, CA USA
[5] Novo Nordisk AS, Soborg, Denmark
[6] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada
来源：
DIABETOLOGIA | 2013年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1027
引用
收藏
页码：S412 / S413
页数：2
相关论文
共 50 条
  • [1] Liraglutide add-on to insulin degludec plus metformin vs addition of a single dose of insulin aspart to the largest meal in patients with Type 2 diabetes
    Russell-Jones, D.
    Mathieu, C.
    Rodbard, H. W.
    Cariou, B.
    Handelsman, Y.
    Philis-Tsimikas, A.
    Francisco, A. M. Ocampo
    Rana, A.
    Zinman, B.
    DIABETIC MEDICINE, 2014, 31 : 52 - 52
  • [2] Comparison of Addition of Liraglutide to Insulin Degludec Plus Metformin vs. Addition of a Single Dose of Rapid-Acting Insulin Analog to Largest Meal in Type 2 Diabetes
    Mathieu, Chantal
    Rodbard, Helena W.
    Cariou, Bertrand
    Handelsman, Yehuda
    Philis-Tsimikas, Athena
    Francisco, Ann Marie Ocampo
    Rana, Azhar
    Zinman, Bernard
    DIABETES, 2013, 62 : A231 - A231
  • [3] Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes
    Oya, Junko
    Nakagami, Tomoko
    Hasegawa, Yukiko
    Kondo, Yuichiro
    Katamine, Aki
    Shimizu, Mika
    Kubota, Ryo
    Suda, Rika
    Babazono, Tetsuya
    DIABETOLOGY INTERNATIONAL, 2024, 15 (02) : 237 - 243
  • [4] Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes
    Junko Oya
    Tomoko Nakagami
    Yukiko Hasegawa
    Yuichiro Kondo
    Aki Katamine
    Mika Shimizu
    Ryo Kubota
    Rika Suda
    Tetsuya Babazono
    Diabetology International, 2024, 15 : 237 - 243
  • [5] Evaluation of the CGMs in type-2 diabetic patients switched from Liraglutide and Insulin Degludec to Liraglutide and Insulin Degludec/Aspart
    Kakizaki, Yusuke
    Fujita, Tomoko
    Takahashi, Tomono
    Miwa, Takashi
    Odawara, Masato
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S111 - S111
  • [6] A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)
    Mathieu, C.
    Rodbard, H. W.
    Cariou, B.
    Handelsman, Y.
    Philis-Tsimikas, A.
    Francisco, A. M. Ocampo
    Rana, A.
    Zinman, B.
    DIABETES OBESITY & METABOLISM, 2014, 16 (07): : 636 - 644
  • [7] Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
    Onishi, Yukiko
    Yamada, Kenichi
    Zacho, Jeppe
    Ekelund, Jan
    Iwamoto, Yasuhiko
    JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (02) : 210 - 217
  • [8] Efficacy and Safety of Insulin Aspart 30 and Insulin Degludec/Aspart vs. Basal Insulin in Patients with Type 2 Diabetes: A Meta-analysis
    Mishriky, Basem M.
    Tanenberg, Robert J.
    Cummings, Doyle M.
    DIABETES, 2017, 66 : A252 - A252
  • [9] Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes
    Sarah L. Greig
    Lesley J. Scott
    Drugs, 2015, 75 : 1523 - 1534
  • [10] Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes
    Greig, Sarah L.
    Scott, Lesley J.
    DRUGS, 2015, 75 (13) : 1523 - 1534
12345